Favipiravir shows significant improvement in COVID clinical cure: Glenmark
Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus's replication cycle.
Mumbai: A randomized, controlled Phase 3 clinical study conducted by Glenmark Pharmaceuticals showed the oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19.
The IJID is a globally reputed, peer-reviewed, pubmed indexed, open access journal published monthly by the International Society for Infectious Diseases, USA. The published findings will also appear in the print edition of the journal in the coming weeks. The publication on the study titled "Efficacy and Safety of Favipiravir, an Oral RNADependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial" was authored by Dr. Zarir .F. Udwadia and other co-authors .